Carasent

24,30 SEK

-0,82%

1.642 følger denne virksomhed

CARA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

-0,82 %
+0,83 %
+2,53 %
-11,48 %
-10,33 %
0,00 %
+68,03 %
-35,33 %
+9,87 %

Carasent is an IT company. The company delivers products and services within communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security and backup solutions. Customers are mainly found within health and care, finance and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.

Læs mere
Markedsværdi
1,76 mia. SEK
Aktieomsætning
1,7 mio. SEK
Omsætning
343,82 mio.
EBIT %
2,74 %
P/E
48,6
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
10.7
2026

Delårsrapport Q2'26

15.10
2026

Delårsrapport Q3'26

4.2
2027

Årsrapport '26

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Forumopdateringer
Carnegielta har bestilt analyse før Q4 Inderes Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview -... Carnegie has published a new commissioned research report on Carasent.To access the full report and subscribe to future updates, visit https://www.carnegie...
redeye.se Carasent (Q3 Review): In good shape for exciting 2026 Redeye retains its positive view of Carasent following the Q3 report. Organic ARR growth remains solid, and margins are improving substantially. The company has several ongoing growth initiatives tha Carasents rentabilitetsven...
Jeg har Carasent ASA for flere tusinde. Det handles ikke længere, så jeg sidder fast med aktierne. Jeg troede, der ville være en automatisk ombytning til Carasent AB… Er der andre i samme situation? Hvad skal jeg gøre? Hvordan forhindrer man dette i fremtiden?
redeye.se Carasent: Back in Shape in 2024 – More to Come Redeye retains its positive view of Carasent following the Q4 report. Despite a somewhat softer Q4 report than expected and a softened outlook for H1 2025, we changed our Base Case driven by revised Ny basiscase SEK28 (NOK26...
Redeye forventninger til regnskabet den 13.2.
Inderes First day of trading in Carasent AB (publ) on Nasdaq Stockholm - Inderes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND...
Hvilken mægler? Kontakt dem, så skal det nok ordne sig.
Besøg forummet